Komori
Chordia Therapeutics (190A) · TargetFirst statedLatest Other Disclosures (2026-09-30): "Advanced"

Expansion of rogocekib indications to ovarian cancer and MDS

First written in FY2025. 2 of 3 entries say "Advanced", first in 2026-05-19. Latest entry: 2026-09-30.

3entries
2years
2from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2025Advanced2026-05-19 – 2026-09-302025: 120252026: 22026
Same theme, other companies
rogocekib development for expanded indications in ovarian cancer and MDSA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  2. FY2025First statedAnnual report

    「In addition, responses to rogocekib have been confirmed in ovarian cancer and MDS in a domestic Phase 1 clinical trial. We will proceed with development in these cancer types in turn, expand the indications and work to maximize the product value of rogocekib.」

    In addition to the previous plan prioritizing AML as the indication, the company newly stated its goal of proceeding with development in ovarian cancer and MDS in turn and expanding the indications.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Chordia Therapeutics's next results are scheduled for 2026-10-15. Read the earnings preview It last moved in the Other Disclosures of 2026-09-30: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.